OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

M Ferrante; S Danese; M Chen; G D'Haens; S Ghosh; T Hisamatsu; V Jairath; J Kierkus; L Peyrin-Biroulet; B Siegmund; S M Bragg; W Crandall; T Hunter Gibble; Z Lin; M Ugolini Lopes; N Morris; H Carlier; B Sands

doi:10.1093/ecco-jcc/jjad212.0005

OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

M Ferrante
, S Danese
, M Chen
, G D'Haens
, S Ghosh
, T Hisamatsu
, V Jairath
, J Kierkus
, L Peyrin-Biroulet
, B Siegmund
, S M Bragg
, W Crandall
, T Hunter Gibble
, Z Lin
, M Ugolini Lopes
, N Morris
, H Carlier
, B Sands

APC Microbiome Ireland

University Hospital Leuven
Università Vita-Salute San Raffaele
Sun Yat-Sen University
Amsterdam University Medical Centers
Kyorin University
Western University
The Children's Memorial Health Institute
University Lorraine
Charité – Universitätsmedizin Berlin
Eli Lilly
Mount Sinai

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	i7-i9
Journal	Journal of Crohn's and Colitis
DOIs	https://doi.org/10.1093/ecco-jcc/jjad212.0005
Publication status	Published - 24 Jan 2024
Event	19th Congress of ECCO - Stockhom, Sweden Duration: 21 Jul 2024 → 24 Jul 2024

Access to Document

10.1093/ecco-jcc/jjad212.0005Licence: Other

https://academic.oup.com/ecco-jcc/article/18/Supplement_1/i7/7586100

Cite this

Ferrante, M., Danese, S., Chen, M., D'Haens, G., Ghosh, S., Hisamatsu, T., Jairath, V., Kierkus, J., Peyrin-Biroulet, L., Siegmund, B., Bragg, S. M., Crandall, W., Hunter Gibble, T., Lin, Z., Ugolini Lopes, M., Morris, N., Carlier, H., & Sands, B. (2024). OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. Journal of Crohn's and Colitis, i7-i9. https://doi.org/10.1093/ecco-jcc/jjad212.0005

@article{725b5b895bba46a3b934b31fcfe23d79,

title = "OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn{\textquoteright}s Disease: results of the treat-through VIVID 1 study",

author = "M Ferrante and S Danese and M Chen and G D'Haens and S Ghosh and T Hisamatsu and V Jairath and J Kierkus and L Peyrin-Biroulet and B Siegmund and Bragg, \{S M\} and W Crandall and \{Hunter Gibble\}, T and Z Lin and \{Ugolini Lopes\}, M and N Morris and H Carlier and B Sands",

year = "2024",

month = jan,

day = "24",

doi = "10.1093/ecco-jcc/jjad212.0005",

language = "English",

pages = "i7--i9",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

note = "19th Congress of ECCO ; Conference date: 21-07-2024 Through 24-07-2024",

}

Ferrante, M, Danese, S, Chen, M, D'Haens, G, Ghosh, S, Hisamatsu, T, Jairath, V, Kierkus, J, Peyrin-Biroulet, L, Siegmund, B, Bragg, SM, Crandall, W, Hunter Gibble, T, Lin, Z, Ugolini Lopes, M, Morris, N, Carlier, H & Sands, B 2024, 'OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study', Journal of Crohn's and Colitis, pp. i7-i9. https://doi.org/10.1093/ecco-jcc/jjad212.0005

TY - JOUR

T1 - OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

AU - Ferrante, M

AU - Danese, S

AU - Chen, M

AU - D'Haens, G

AU - Ghosh, S

AU - Hisamatsu, T

AU - Jairath, V

AU - Kierkus, J

AU - Peyrin-Biroulet, L

AU - Siegmund, B

AU - Bragg, S M

AU - Crandall, W

AU - Hunter Gibble, T

AU - Lin, Z

AU - Ugolini Lopes, M

AU - Morris, N

AU - Carlier, H

AU - Sands, B

PY - 2024/1/24

Y1 - 2024/1/24

U2 - 10.1093/ecco-jcc/jjad212.0005

DO - 10.1093/ecco-jcc/jjad212.0005

M3 - Meeting abstract

SN - 1873-9946

SP - i7-i9

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

T2 - 19th Congress of ECCO

Y2 - 21 July 2024 through 24 July 2024

ER -